{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:48:55Z","timestamp":1777783735114,"version":"3.51.4"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Office of the Assistant Secretary for Preparedness and Response","award":["HHSO100201500029C"],"award-info":[{"award-number":["HHSO100201500029C"]}]},{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201500029C"],"award-info":[{"award-number":["HHSO100201500029C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSO100201500029C"],"award-info":[{"award-number":["HHSO100201500029C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2022,12,21]]},"abstract":"<jats:p>Increasing antibiotic resistance and emergence of pan-resistant isolates threaten the ability to control infections and to provide many other medical interventions such as surgery and chemotherapy, among others. New therapies are required to control emerging resistance mechanisms, including the increase in metallo-\u03b2-lactamases.<\/jats:p>","DOI":"10.1128\/spectrum.03601-22","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T14:02:57Z","timestamp":1667829777000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales"],"prefix":"10.1128","volume":"10","author":[{"given":"C. J.","family":"Kelley","sequence":"first","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kennedy-Mendez","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Walser","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. F.","family":"Arhin","sequence":"additional","affiliation":[{"name":"Pfizer Canada, Kirkland, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Pillar","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Hufnagel","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_3_3_2","volume-title":"Tackling drug-resistant infections globally: final report and recommendations.","author":"O\u2019Neill J","year":"2016","unstructured":"O\u2019Neill J. 2016. Tackling drug-resistant infections globally: final report and recommendations. HM Government and Wellcome Trust, London, UK."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6601a7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S337611"},{"key":"e_1_3_3_6_2","volume-title":"Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria.","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. 2019. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. CDC, Atlana, GA, USA."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0159-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01009-09"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00897-16"},{"key":"e_1_3_3_11_2","unstructured":"FDA. 2015. AVYCAZ for injection. https:\/\/www.researchid.com\/wp-content\/uploads\/2018\/03\/cphln_cpe_2008-2017_public_final.pdf."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz830"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S349004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00774-09"},{"key":"e_1_3_3_16_2","volume-title":"Canadian Public Health Laboratory Network (CPHLN) voluntary reporting of carbapenemase-producing Enterobacteriaceae.","author":"Canadian Public Health Laboratory Network","year":"2018","unstructured":"Canadian Public Health Laboratory Network. 2018. Canadian Public Health Laboratory Network (CPHLN) voluntary reporting of carbapenemase-producing Enterobacteriaceae. Public Health Agency of Canada, Ottawa, Ontario, Canada. https:\/\/www.researchid.com\/wp-content\/uploads\/2018\/03\/cphln_cpe_2008-2017_public_final.pdf."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01008-17"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa549"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw231"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10081012"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa586"},{"key":"e_1_3_3_22_2","unstructured":"CLSI. 2022. M100Ed32. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute Wayne PA USA."},{"key":"e_1_3_3_23_2","unstructured":"CLSI. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute Wayne PA USA."},{"key":"e_1_3_3_24_2","unstructured":"CLSI. 2018. M23Ed5. Development of in vitro susceptibility testing criteria and quality control parameters. Clinical and Laboratory Standards Institute Wayne PA USA."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00486-21"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz226"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3168\/jds.2014-8027"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.11.002"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03601-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03601-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T14:42:58Z","timestamp":1671633778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03601-22"}},"subtitle":[],"editor":[{"given":"Brian","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12,21]]}},"alternative-id":["10.1128\/spectrum.03601-22"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03601-22","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,21]]},"assertion":[{"value":"2022-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03601-22"}}